Search results for "Predictive factors"

showing 10 items of 17 documents

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

2018

The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I–O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice. A thorough patient evaluation and close clinical monito…

0301 basic medicineOncologymedicine.medical_specialtyLung NeoplasmsImmune-checkpoint inhibitorSettore MED/06 - Oncologia MedicaImmune-checkpoint inhibitorsBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Antibodies Monoclonal; B7-H1 Antigen; Biomarkers; CTLA-4 Antigen; Carcinoma Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Patient Selection; Hematology; OncologyAntibodiesB7-H1 Antigen03 medical and health sciences0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungInternal medicineMonoclonalmedicineHumansCTLA-4 AntigenNeutrophil to lymphocyte ratioNon-Small-Cell LungLung cancerHepatitisPerformance statusbusiness.industryPatient SelectionCarcinomaInterstitial lung diseaseAntibodies MonoclonalBronchiolitis obliterans organizing pneumoniaBiomarkerHematologymedicine.diseaseBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Hematology; OncologyClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyPredictive factorbusinessBiomarkersImmune-oncologyPredictive factorsProgressive diseaseCritical Reviews in Oncology/Hematology
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis.

2003

To identify predictive factors of response to interferon alpha (IFN-alpha) plus ribavirin therapy in patients with chronic hepatitis C (CHC), the presence of lymphadenopathy (LyA) of the hepatoduodenal ligament and other variables were investigated. A total of 110 patients with histologically proven CHC were enrolled in this study. Ultrasound (US) was performed at the start and end of therapy and 6 months after stopping therapy. At baseline, LyA was present in 35 (43.7%) of 80 patients with alanine aminotransferase (ALT) values and grading was significantly higher than in the LyA-negative group. LyA was more frequent in nonresponders (nonR) than in relapsers (relR) or sustained responders (…

AdultMalemedicine.medical_specialtyAcoustics and UltrasonicsEnd of therapyBiophysicsAlpha interferonGastroenterologyAntiviral Agentschemistry.chemical_compoundInternal medicineRibavirinmedicineHumansUltrasound Lymphadenopathy Chronic hepatitis C Treatment Predictive factors.Radiology Nuclear Medicine and imagingProspective StudiesAlanine aminotransferaseLymph nodeLymphatic DiseasesUltrasonographyHepatitisRadiological and Ultrasound Technologybusiness.industryRibavirinInterferon-alphaHepatoduodenal ligamentHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureLogistic ModelsTreatment OutcomechemistryDrug Therapy CombinationFemaleLymphbusinessUltrasound in medicinebiology
researchProduct

Adhesive Small Bowel Obstruction: Predictive Factors of Lack of Response in Conservative Management with Gastrografin

2015

<b><i>Background:</i></b> Gastrografin represents a useful tool in the diagnosis and management of adhesive small bowel obstruction (ASBO). The aim of this study is to identify variables with negative influence in nonoperative management with gastrografin. <b><i>Methods:</i></b> From August 2008 to March 2013, 223 consecutive patients with 235 episodes of ASBO were included and received gastrografin. A protocol for prospective data collection was developed. In order to explore factors related to the failure of nonoperative treatment, univariate and multivariate analysis were performed. <b><i>Results:</i></b> One hundred…

AdultMalemedicine.medical_specialtyMultivariate analysisConservative managementClinical Decision-MakingGastrografinContrast MediaProspective dataTissue Adhesions030230 surgery03 medical and health sciencesPostoperative Complications0302 clinical medicineIntestine SmallmedicineHumansProspective StudiesAdhesive small bowel obstructionProspective cohort studyAgedDiatrizoate MeglumineAged 80 and overbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryRadiographyBowel obstructionClinical trialTreatment Outcome030220 oncology & carcinogenesisCohortFemaleSurgerybusinessAdhesive syndromeIntestinal ObstructionPredictive factorsAbdominal surgery
researchProduct

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

2023

BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with aveluma…

Cancer Researchpredictive factorsOncologyskin cancer non melanomaavelumabimmunotherapybody mass index - BMIMerkel cell carcinoma (MCC)Frontiers in Oncology
researchProduct

The Symmetry and Predictive Factors in Two-Stage Bilateral Hip Replacement Procedures

2021

Background: Approximately 10–25% of total hip replacement patients undergo a bilateral procedure. The purpose of this study was to compare selected parameters associated with the first and second hip arthroplasty in patients undergoing two-stage treatment due to bilateral hip osteoarthritis and establish the predictive factors for the second procedure. Methods: This study compared the data on bilateral total hip replacement surgeries conducted in the period between 2017 and 2021 (42 patients). The following parameters from the first and second procedure were compared: the prosthetic stem, head, and insert cup size

Head sizemedicine.medical_specialtypredictive factorsPhysics and Astronomy (miscellaneous)business.industryGeneral MathematicsHip replacement (animal)SurgeryTotal hip replacement surgeryChemistry (miscellaneous)QA1-939Computer Science (miscellaneous)Hip osteoarthritisMedicinehip replacementIn patientStage (cooking)businessbilateralHospital staytwo-stageMathematicssymmetry; predictive factors; two-stage; bilateral; hip replacementsymmetryTotal hip arthroplastySymmetry
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

EAU Guidelines on Vesicoureteral Reflux in Children

2012

Context: Primary vesicoureteral reflux (VUR) is a common congenital urinary tract abnormality in children. There is considerable controversy regarding its management. Preservation of kidney function is the main goal of treatment, which necessitates identification of patients requiring early intervention.Objective: To present a management approach for VUR based on early risk assessment.Evidence acquisition: A literature search was performed and the data reviewed. From selected papers, data were extracted and analyzed with a focus on risk stratification. The authors recognize that there are limited high-level data on which to base unequivocal recommendations, necessitating a revisiting of thi…

MalePediatricsACID SCINTIGRAPHYmedicine.medical_treatmentKidneyurologic and male genital diseasesPediatricsVOIDING CYSTOURETHROGRAPHYURETERAL REIMPLANTATIONMedicineAntibiotic prophylaxisFamily historyChildChildrenNEONATAL HYDRONEPHROSISReimplantationUrinary tract infectionVesicoureteral refluxDiagnostic Techniques Urologicalfemale genital diseases and pregnancy complicationsAnti-Bacterial AgentsTreatment OutcomeRenal scarringBulking agentsEAUPREDICTIVE FACTORSChild PreschoolPredictive value of testsUrologic Surgical ProceduresFemaleRisk assessmentmedicine.medical_specialtyUrologyUrinary systemContext (language use)GuidelinesVesicoureteral refluxURINARY-TRACT-INFECTIONANTIBIOTIC-PROPHYLAXISPredictive Value of TestsHumansWatchful WaitingVesico-Ureteral RefluxProphylaxisbusiness.industryInfantEndoscopymedicine.diseaseVURSurgeryISOLATED ANTENATAL HYDRONEPHROSISEarly DiagnosisRENAL DAMAGESPONTANEOUS RESOLUTIONLaparoscopybusinessWatchful waitingEuropean Urology
researchProduct

Predictive Factors of Abdominal Compartment Syndrome in Neonatal Age

2014

In the pediatric population, abdominal compartment syndrome (ACS) is a known complication of abdominal wall defect repair. However, there are only few reports on ACS in newborns and only a proposal of critical intra-abdominal pressure value (IAP) in term newborns, absent in preterm newborns. Although the prevalent clinical sign is tense abdominal distension, it may be difficult to distinguish ACS from pathologies that will not require decompression. The purpose of this study was to identify predictors for ACS and therefore morbidity or mortality indicators. We reviewed newborns presenting with tense abdominal distension and end organ failure. Anamnestic, clinical, laboratory, and instrument…

MalePediatricsmedicine.medical_specialtyNeonatal intensive care unitAbdominal compartment syndromePopulationGestational AgeAbdominal wallSettore MED/38 - Pediatria Generale E SpecialisticaIntubation IntratrachealHumansMedicineLactic AcideducationAbdominal Compartment Syndrome Predictive Factors in Neonatal AgeRetrospective Studieseducation.field_of_studybusiness.industryIncidenceAbdominal wall defectAbdominal WallInfant NewbornObstetrics and GynecologyGestational ageAbdominal distensionmedicine.diseaseRespiration ArtificialSurgerymedicine.anatomical_structureCase-Control StudiesPediatrics Perinatology and Child HealthApgar ScoreFemaleIntra-Abdominal HypertensionIntra-Abdominal Hypertensionmedicine.symptombusinessAmerican Journal of Perinatology
researchProduct

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct